Biomarker-Driven Precision Oncology in Advanced Gastroesophageal Adenocarcinoma: Current Standards and Future Directions
: Advanced gastroesophageal adenocarcinomas (GEA) have undergone a major therapeutic shift from empiric chemotherapy toward biomarker-driven precision oncology. Routine incorporation of immunohistochemistry (IHC), in situ hybridization, next-generation sequencing (NGS), and liquid biopsy have enabled identification of...